Article
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
European journal of cancer (Oxford, England : 1990) - 1 May 2021
Provencio Mariano, Serna-Blasco Roberto, Franco Fabio, Calvo Virgina, Royuela Ana, Auglytė Milda, Sánchez-Hernández Alfredo, de Julián Campayo María, García-Girón Carlos, Dómine Manuel, Blasco Ana, Sánchez José M, Oramas Juana, Bosch-Barrera Joaquim, Sala María Á, Sereno María, Ortega Ana L, Chara Luis, Hernández Berta, Padilla Airam, Coves Juan, Blanco Remedios, Balsalobre José, Mielgo Xabier, Bueno Coralia, Jantus-Lewintre Eloisa, Molina-Vila Miguel Á, Romero Atocha
Abstract excerpt
BACKGROUND: Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential first- or second-generation tyrosine kinase inhibitors (TKIs) followed by osimertinib for all patients. It is impossible to predict which patients are at...
Topics
Join the communities discussing this publication.